Arrowstreet Capital’s BeOne Medicines Ltd ONC Stock Holding History

Arrowstreet Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$203M	Buy	553,389 +303,631	+122%	+$104M	0.09%	214
2026 Q2	$71.2M	Buy	249,758 +139,172	+126%	+$41M	0.03%	445
2026 Q1	$32.8M	Buy	110,586 +54,260	+96%	+$17.6M	0.02%	612
2025 Q4	$17.1M	Buy	56,326 +592	+1%	+$194K	0.01%	782
2025 Q3	$19M	Buy	55,734 +53,649	+2,573%	+$16.3M	0.01%	748
2025 Q2	$505K	Sell	2,085 -36,777	-95%	-$9.02M	﹤0.01%	1748
2025 Q1	$10.6M	Buy	+38,862	New	+$9.09M	0.01%	796
2021 Q1	–	Sell	-30,782	Closed	-$7.95M	–	2583
2020 Q4	$7.95M	Buy	+30,782	New	+$8.47M	0.01%	982
2018 Q4	–	Sell	-49,393	Closed	-$8.51M	–	1533
2018 Q3	$8.51M	Sell	49,393 -3,207	-6%	-$539K	0.02%	441
2018 Q2	$8.09M	Buy	+52,600	New	+$9.38M	0.02%	454

Other funds holding ONC

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $73.6B AUM 18.65% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Arrowstreet Capital's ONC Position: Q3 2026 in Review

Arrowstreet Capital increased its BeOne Medicines Ltd (ONC) stake by 122% in Q3 2026, buying an estimated $104M and bringing the position to 553,389 shares worth $203M. The position accounts for 0.09% of the portfolio, ranked #214.

Arrowstreet Capital first reported a position in ONC in Q2 2018 and has held it in 10 quarters since. 260 funds tracked by Wall St. Rank hold ONC as of Q3 2026.

Arrowstreet Capital held 553,389 shares of BeOne Medicines Ltd worth $203M as of Q3 2026.
Arrowstreet Capital bought 303,631 BeOne Medicines Ltd shares in Q3 2026, an estimated $104M.
BeOne Medicines Ltd made up 0.09% of Arrowstreet Capital's portfolio in Q3 2026, its #214 holding.
Arrowstreet Capital first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 10 quarters since.
260 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.